Vital funding for ovarian cancer research

 Threegenerationspr
27 Jan 2014 14:59:51.043

PA 26/14

The University of Nottingham is to lead a research project looking at developing new drugs to target both drug resistant and BRCA 1 and 2 gene mutation ovarian cancer.

The research, funded by the national charity, Target Ovarian Cancer, is part of a high profile collaboration with the National Institutes of Health, USA, and the University of Newcastle. Such drugs could have the potential to help save countless lives. 

The project is led by Dr Srinivasan Madhusudan in the School of Medicine. He said: “Resistance to chemotherapy is a major problem in ovarian cancer. This research will allow the investigation of FEN1, a key DNA repair protein, for the first time in ovarian cancer. If successful the project will have the potential to benefit very many ovarian cancer patients who suffer from platinum resistance. If we are able to demonstrate that FEN1 inhibitors can overcome platinum resistance and can also selectively target BRCA deficient ovarian cancer cell lines, we may be able to develop a new treatment strategy for ovarian cancer. This has the potential to improve survival in patients with advanced ovarian cancer.”

Click here for full story

Story credits

More information is available from Dr Srinivasan Madhusudan on +44 (0)115 823 1850, Srinivasan.madhusudan@nottingham.ac.uk; or Sharon Harriott at Target Ovarian Cancer on +44 (0)20 7923 5476, sharriott@targetovarian.org.uk
Lindsay Brooke

Lindsay Brooke - Media Relations Manager

Email: lindsay.brooke@nottingham.ac.uk Phone: +44 (0)115 951 5751 Location: University Park

Additional resources

No additional resources for this article

Related articles

No related articles

Media Relations - External Relations

The University of Nottingham
YANG Fujia Building
Jubilee Campus
Wollaton Road
Nottingham, NG8 1BB

telephone: +44 (0) 115 951 5798
email: pressoffice@nottingham.ac.uk